Copy number of chromosome 17 but not HER2 amplification predicts clinical outcome of patients with pancreatic ductal adenocarcinoma.

PURPOSE To determine the frequency and the potential clinical use of HER2 (17q21) gene amplification and chromosome 17 aneuploidy in pancreatic ductal adenocarcinoma (PDAC). MATERIALS AND METHODS Serial tissue sections of 50 resected PDACs were analyzed with chromogenic in situ hybridization using locus-specific HER2 probes and centromeric probes for chromosome 17. Centromeric probes for chromosome 7 and 8 were hybridized to confirm ploidy levels. Expression of HER2 protein was assessed by immunohistochemistry. Correlations of experimental findings with clinical and follow-up data were tested. RESULTS The HER2 gene locus was frequently (24%) amplified in PDAC and the rate of overexpression (2+ and 3+) was 10%, but no prognostic significance was found. Copy number analysis of chromosomes 7, 8, and 17 revealed disomic (40%), trisomic (36%), and hypertetrasomic (24%) tumors. Compared with patients with disomic tumors, patients with hypertetrasomic tumors exhibited a significantly decreased relapse-free and overall survival (5.0 v 13.0 months, P = .0144 and 7.0 v 20.0 months, P = .0099, respectively). Multivariate analysis confirmed the independent prognostic significance of hypertetrasomy. CONCLUSION Tumor ploidy levels correlate with prognosis of PDAC patients, indicating characteristic biologic properties of PDAC with high chromosomal instability. In contrast, no prognostic influence on patient outcome was found for the amplification of the HER2 oncogene or p185(HER2) overexpression. Therefore, evaluation of ploidy levels offers new opportunities for patient stratification in clinical trials and enables novel approaches to study the well-known aggressiveness of PDAC.

[1]  H. Friess,et al.  [Adjuvant and additive therapy for cancer of the pancreas]. , 2003, Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen.

[2]  R. Kåresen,et al.  Assessment of HER‐2/neu overexpression and/or gene amplification in breast carcinomas: should in situ hybridization be the method of choice? , 2003, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[3]  C. Earle,et al.  Prognostic Factors Following Curative Resection for Pancreatic Adenocarcinoma: A Population-Based, Linked Database Analysis of 396 Patients , 2003, Annals of surgery.

[4]  A. Andrén-sandberg,et al.  Resection for Pancreatic Cancer in the New Millennium , 2002, Pancreatology.

[5]  M. Schäfer,et al.  Evidence-Based Pancreatic Head Resection for Pancreatic Cancer and Chronic Pancreatitis , 2002, Annals of surgery.

[6]  A. Potti,et al.  Role of immunohistochemical identification of Her-2/neu and detection of variability in overexpression in pancreatic carcinoma. , 2002, Anticancer research.

[7]  K. Okita,et al.  Interglandular cytogenetic heterogeneity detected by comparative genomic hybridization in pancreatic cancer. , 2002, Cancer research.

[8]  Jacques Ferlay,et al.  Estimating the world cancer burden: Globocan 2000 , 2001, International journal of cancer.

[9]  D. Iannitti,et al.  Overexpression of the HER-2/ neu Oncogene in Pancreatic Adenocarcinoma , 2001, American journal of clinical oncology.

[10]  D. Gisselsson,et al.  Multivariate analyses of genomic imbalances in solid tumors reveal distinct and converging pathways of karyotypic evolution , 2001, Genes, chromosomes & cancer.

[11]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[12]  H. Friess,et al.  Therapy for pancreatic cancer with a recombinant humanized anti-HER2 antibody (herceptin) , 2001, Journal of Gastrointestinal Surgery.

[13]  M. Sliwkowski,et al.  Overexpression of HER2/neu in solid tumours: an immunohistochemical survey , 2001, Histopathology.

[14]  Y. Yarden,et al.  Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.

[15]  D. Slamon,et al.  Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  D. Visscher,et al.  Analysis of chromosome aneuploidy in breast carcinoma progression by using fluorescence in situ hybridization. , 1999, Laboratory investigation; a journal of technical methods and pathology.

[17]  B Johansson,et al.  Comparative genomic hybridization reveals frequent gains of 20q, 8q, 11q, 12p, and 17q, and losses of 18q, 9p, and 15q in pancreatic cancer , 1997, Genes, chromosomes & cancer.

[18]  F. Sarkar,et al.  HER‐2/neu Expression in Pancreatic Adenocarcinoma: Relation to Tumor Differentiation and Survival , 1997, Pancreas.

[19]  S. Goodman,et al.  Immunohistochemical evaluation of HER-2/neu expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms. , 1996, Human pathology.

[20]  J. Niederhuber,et al.  The national cancer data base report on pancreatic cancer , 1995, Cancer.

[21]  M. Imamura,et al.  Elevated serum c-erbB-2 protein levels in patients with pancreatic cancer: correlation to metastasis and shorter survival. , 1995, Oncology.

[22]  P. Grambsch,et al.  Proportional hazards tests and diagnostics based on weighted residuals , 1994 .

[23]  H. Battifora.  HER2/neu immunostaining in pancreatic carcinoma. , 1994, Human pathology.

[24]  H. Friess,et al.  Overexpression of HER2/neu oncogene in human pancreatic carcinoma. , 1993, Human pathology.

[25]  A. Tannapfel,et al.  Ductal adenocarcinoma of the pancreas , 1992, International journal of pancreatology : official journal of the International Association of Pancreatology.

[26]  D. Pinkel,et al.  ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[27]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[28]  E. Berg,et al.  World Health Organization Classification of Tumours , 2002 .

[29]  B. Matouš,et al.  Prognostic significance of c-erbB-2 gene expression in pancreatic cancer patients. , 2001, Neoplasma.